Pronunciation roe-LA-pi-tant Routes of
administration By mouth (tablets) Legal status US: ℞-only Molar mass 500.476 g/mol | Trade names Varubi ATC code A04AD14 (WHO) Metabolism Protein binding 99.8% | |
Rolapitant (INN, trade name Varubi vuh-ROO-bee, code name SCH 619734) is a drug originally developed by Schering-Plough and licensed for clinical development by Tesaro, which acts as a selective NK1 receptor antagonist (antagonist for the NK1 receptor). It has been approved as a medication for the treatment of chemotherapy-induced nausea and vomiting (CINV) after clinical trials showed it to have similar or improved efficacy and some improvement in safety over existing drugs for this application.
Contents
Reducing nausea and vomiting associated with cisplatin based chemotherapy with rolapitant
Medical uses
Rolapitant is indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.